|
|
|
|
|
Highlights from the 2022 American Society of Clinical Oncology |
|
|
|
|
| Poster Session: Genitourinary Cancer--Kidney and Bladder
|
|
| Long-Term Outcomes in Patients with Advanced Urothelial Carcinoma Who Received Avelumab First-Line Maintenance with or Without Second-Line Treatment: Exploratory Analyses from JAVELIN Bladder 100
|
| Joaquim Bellmunt, MD, Ph.D.
|
| Joaquim Bellmunt examined the long-term outcomes from the JAVELIN Bladder 100 trial among patients receiving first-line avelumab maintenance therapy, with a specific focus on the use of subsequent second-line therapy. This exploratory analysis of the JAVELIN Bladder 100 trial shows the second-line treatment is common following avelumab maintenance therapy. Long-term overall survival may be observed with or without second-line treatment.
|
|
|
|
|
|
| Association of DNA Damage Response Gene Mutations and Response to Neoadjuvant Cisplatin-Based Chemotherapy in MIBC Patients Enrolled Onto SWOG S1314 |
| Gopa Iyer, MD |
| Gopa Iyer discussed the association of DNA damage response gene mutations and response to neoadjuvant cisplatin-based chemotherapy in MIBC patients enrolled in SWOG S1314. In patients managed with neoadjuvant chemotherapy and radical cystectomy on S1314, both ERCC2 mutations and deleterious DDR gene mutations correlated with pathologic response (<pT2 and pT0). Any deleterious DDR gene mutation was associated with improved PFS. |
|
|
|
|
|
| Healthcare Resource Utilization and Costs for Patients With mRCC Receiving First-Line Pembrolizumab + Axitinib or Ipilimumab + Nivolumab
|
| Neil Shah, MBBS
|
| Neil Shah discussing healthcare resource utilization and costs for patients with metastatic renal cell carcinoma (RCC) receiving first-line pembrolizumab + axitinib or ipilimumab + nivolumab. This is one of the first studies to comprehensively assess healthcare resource utilization counts and associated costs in newer immuno-oncology and TKI-based therapies of metastatic RCC patients in the real-world setting.
|
|
|
|
|
|
| The Prognostic Role of Nephrectomy in Patients With mRCC Treated With Immunotherapy According to the Novel Prognostic Meet-URO Score: Sub-Analysis of the Meet-URO 15 Study
|
| Sara E. Rebuzzi, MD
|
| Sara Rebuzzi discussed a sub-analysis of the Meet-URO 15 study assessing the prognostic role of nephrectomy in patients with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score.
|
|
|
|
|
|
| Progression-Free Survival After Second Line of Therapy (PFS-2) for Metastatic Clear Cell RCC in Patients Treated With First-Line Immunotherapy Combinations
|
| Kelly N. Fitzgerald, MD, Ph.D.
|
| Kelly Fitzgerald discussed progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (RCC) in patients treated with first-line immunotherapy combinations. This was a retrospective analysis performed on patients with clear cell RCC treated at Memorial Sloan Kettering Cancer Center between January 1, 2014 and December 30, 2020, in cohorts defined by 1st line: IO/IO or TKI/IO.
|
|
|
|
|
|
|
|
|
|
|
| Sequential Immunotherapy in Rare Variant Renal Cell Carcinoma Final Report of UNISoN (ANZUP 1602): Nivolumab Then Ipilimumab + Nivolumab in Advanced Nonclear Cell Renal Cell Carcinoma
|
| Ciara Conduit, MD
|
| Ciara Conduit discussed the final report of UNISoN (ANSUP 1602) testing nivolumab followed by ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (RCC). Some patients with non-clear cell RCC benefit from nivolumab alone, or addition of ipilimumab when disease is inadequately controlled by nivolumab alone, however most patients have limited benefit from immune checkpoint immunotherapy.
|
|
|
|
|
|
| Prognostic Value of the Lung Immune Prognostic Index in Patients With Untreated Advanced RCC Receiving Nivolumab + Ipilimumab or Sunitinib in the CheckMate 214 Trial
|
| Lucia Carril-Ajuria, MD
|
| Lucia Carril-Ajuria discussing the prognostic value of the lung immune prognostic index in patients with untreated advanced RCC receiving nivolumab + ipilimumab or sunitinib in the CheckMate 214 trial. These results indicate the potential prognostic value of the lung immune prognostic index in patients with untreated advanced RCC receiving nivolumab + ipilimumab or sunitinib.
|
|
|
|
|
|
| Prognostic Factors for Patients With Advanced RCC in the Era of First-Line Treatment With Immune Checkpoint Inhibitors |
| Charlene Mantia, MD |
| Charlene Mantia discussed prognostic factors for patients with advanced renal cell carcinoma (RCC) in the era of first-line treatment with immune checkpoint inhibitors. Strength of the relationships of some prognostic factors in the IMDC model, and of their combination as a prognostic model score, is reduced among patients receiving first-line treatment with combination immune checkpoint inhibitors as compared with VEGFR-targeted TKI. Longer follow-up and survival since initiation of first-line therapy contribute to the diminution of prognostic relationships, as observed in both treatment groups, possibly related to subsequent checkpoint inhibitor administration. |
|
|
|
|
|
| Outcomes With Novel Combinations in Non-Clear Cell RCC: ORACLE Study |
| Deepak Kilari, MD |
| Deepak Kilari discussed the ORACLE study assessing outcomes with novel combinations in non-clear cell renal cell carcinoma (RCC). In this multicenter retrospective analysis, Dr. Kilari and colleagues evaluated the efficacy of combination systemic therapies in patients with non-clear cell RCC. Eligible patients included those with non-clear cell RCC as determined by local genitourinary pathology review and receipt of one of three combination regimens during any line treatment (IO-IO, IO-VEGF, mTOR-VEGF). |
|
|
|
|
|
| Racial Differences in Treatment Patterns and Outcomes of First-Line Therapies for Advanced RCC in the Real-World Setting |
| Daniel M. Geynisman, MD |
| Daniel Geynisman discussed racial differences in treatment patterns and outcomes of first-line therapies for advanced renal cell carcinoma (RCC) in the real-world setting. In this real-world intermediate/poor-risk advanced RCC cohort, no significant difference was observed in the utilization of standard of care IO-based therapy between African American/Black and White American patients. However, with short-term follow-up, clinically meaningful differences in ORR were observed between these cohorts. |
|
|
|
|
|
|
|
|
|
|
| Distinct Outcomes in Hispanic/Latinx and Non-Hispanic/Latinx Patients With Metastatic RCC Treated With First-Line Ipilimumab + Nivolumab |
| Sana Ali, MD |
| Sana Ali discussed outcomes in Hispanic/Latinx and non-Hispanic/Latinx patients with metastatic RCC treated with first-line ipilimumab + nivolumab. Subgroup analyses have reported differences in clinical outcomes by ethnicity in patients receiving immune checkpoint inhibitors. As such, Dr. Ali and colleagues sought to compare real-world outcomes between Hispanic/Latinx and non-Hispanic/Latinx mRCC patients treated with first-line ipilimumab + nivolumab within a safety-net healthcare system and at a tertiary care center in Southern California. |
|
|
|
|
|
| Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by Response to 1L Chemotherapy
|
| Begona Perez-Valderrama, MD
|
| Begona Perez-Valderrama examined the long-term outcomes from the JAVELIN Bladder 100 trial among patients receiving first-line avelumab maintenance therapy, with stratification according to response to first-line induction chemotherapy. This long-term follow-up from JAVELIN Bladder 100 continues to demonstrate a survival benefit to the addition of avelumab maintenance therapy to BSC, independent of response (CR, PR, or SD) to first-line chemotherapy.
|
|
|
|
|
|
| Toripalimab (Anti-PD-1) Monotherapy as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma (POLARIS-03): Two-Year Survival Update and Biomarker Analysis
|
| Haige Chen, MD
|
| Haige Chen discussed the role of toripalimab, an anti-PD-1 antibody, as monotherapy for second-line treatment of metastatic urothelial carcinoma (UC). This extended follow-up shows that toripalimab has a manageable safety profile and encouraging clinical activity in patients with metastatic UC who progress following first-line chemotherapy.
|
|
|
|
|
|
 |
